MNPR
Monopar Therapeutics
$99.27
+4.05 (+4.25%)
At close · Jul 8
Market Cap
$700.05M
Shares
6,699,062
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$99.27
Open$93.87
Day$88.33–100.03
52W$29.18–105.00
Avg vol 30d155K
Short int1.6M · 23.3% float · 12.5d
Short vol70%
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+44%
above
Price vs 50-day avg
+47%
above
RSI (14)
80
overbought
MACD trend
Positive
52-week position
92%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+64%
trailing
6-month return
+48%
trailing
YTD return
+52%
this year
Relative strength
+41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $68 › 200d $69 — 200d above 50d
Institutional flow
Distributing
1 of 81 funds reported for Jun 30 · net -4 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.26% of float · ▼ -1.3% MoM · 12.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
81 holders — near 1-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+44%
Bullish
Price vs 50-day avg
+47%
Bullish
RSI (14)
80
Bearish
MACD trend
Positive
Bullish
52-week position
92%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $68 › 200d $69 — 200d above 50d
Institutional flow
Distributing
1 of 81 funds reported for Jun 30 · net -4 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.26% of float · ▼ -1.3% MoM · 12.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
81 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $29
Now $99 · 92%
52-wk high $105
vs 200-day avg +44%
vs 50-day avg +47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNPR
this stock
Monopar Therapeutics
|
$700.05M | +52.0% | — | — | 23.3% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNPR | +7.2% | +63.8% | +48.1% | +7.2% | +52.0% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +7.4% | +62.9% | +40.6% | +7.4% | +42.7% |